Thus, studies that lack further target validation of the small kinase inhibitors employed need to be considered with caution e.g., the small molecule inhibitor PIK-75, thought to target specifically p110α [192], was later shown to sensitize NSCLC cell lines to TRAIL exclusively via inhibition of CDK9 [132]. The gene discussed is CDK9; the disease is non-small cell lung carcinoma.